FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667060> ?p ?o ?g. }

• W4385667060 endingPage "e2279666" @default.
• W4385667060 startingPage "e2279666" @default.
• W4385667060 abstract "Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Chimeric antigen receptor (CAR) T-cell therapy has exhibited remarkable clinical efficacy in the treatment of relapsed/refractory multiple myeloma (R/RMM), and BCMA-targeted CAR-T cell therapy for R/RMM can achieve an effective rate of more than 90%, with more than 70% of patients obtaining complete response (CR).However, even among patients with CR, relapse and progression of the disease may still occur, and currently there are few reports on the effectiveness of a second CAR-T cell infusion with the same target after progression of disease. Aims: To preliminarily analyze the adverse reactions and clinical efficacy of receiving a second BCMA-targeted CAR-T cell infusion for R/RMM. Methods: The adverse reactions, clinical efficacy and factors affecting the clinical efficacy of a second (including a third) CAR-T cell infusion of R/RMM in the Department of Hematology of Shaanxi Provincial People’s Hospital performed from March 2021 to January 2022 were retrospectively analyzed, and the cut-off time of observation period was at the death of patient or February 26, 2023. Results: A total of 24 patients with R/RMM [males vs. females (13 vs. 11), median age of 57 years (44 years –70 years)] who received a second (including a third) BCMA-CAT-T cell infusion were included in this study, of which 70.8% (17/24) were type IgG, 16.7% (4/24) were type IgD, 4.2%(1/24) was type light-chain, and 8.3% (2/24) were type IgA. For the time from the first BCMA-CAT-T cell therapy, 45.8% (11/24) of the patients were more than 12 months and 54.2% (13/24) were less than 12 months. 54.2% (13/24) of the patients were converted the murine CAR-T to human CAR-T, and 45.8% of the patients received the same humanized infusion. 83.3% (20/24) of the patients received only one CAR-T cell infusion before, and 16.7% (4/24) of the patients received twice in the past. After the BCMA-CAR-T infusion, 58.3 % (14/24) of patients had cytokine release syndrome (CRS), of which 50% (12/24) had grade 1 CRS, 8.3% (2/24) had grade 2 CRS, and only 4.2% (1/24) had grade 1 central nervous system reaction. The median observation time was 5 months (range: 1-18 months). The overall response rate (ORR) was 83.3 % (20/24), among which，41.6% of the patients achieved complete response (CR), 16.7% (4/24) achieved very good partial response (VGPR), and 25% (6/24) achieved partial response (PR). 25% (6/24) of the patients died during the observation period, and the overall survival rate at 12 months was 51.8 %. Summary/Conclusion: The patients with R/RMM who had received BCMA-CAR-T infusion and afterwards showed progressive disease or relapse, could receive a second BCMA-CAR-T therapy. Keywords: CAR-T, Multiple myeloma" @default.
• W4385667060 created "2023-08-09" @default.
• W4385667060 creator A5018964484 @default.
• W4385667060 creator A5019818497 @default.
• W4385667060 creator A5020731258 @default.
• W4385667060 creator A5028935321 @default.
• W4385667060 creator A5032750577 @default.
• W4385667060 creator A5036392227 @default.
• W4385667060 creator A5041125507 @default.
• W4385667060 creator A5045676235 @default.
• W4385667060 creator A5061242940 @default.
• W4385667060 creator A5070241328 @default.
• W4385667060 creator A5070987601 @default.
• W4385667060 creator A5074905580 @default.
• W4385667060 creator A5088705161 @default.
• W4385667060 date "2023-08-01" @default.
• W4385667060 modified "2023-09-27" @default.
• W4385667060 title "P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA" @default.
• W4385667060 doi "https://doi.org/10.1097/01.hs9.0000972528.22796.66" @default.
• W4385667060 hasPublicationYear "2023" @default.
• W4385667060 type Work @default.
• W4385667060 citedByCount "0" @default.
• W4385667060 crossrefType "journal-article" @default.
• W4385667060 hasAuthorship W4385667060A5018964484 @default.
• W4385667060 hasAuthorship W4385667060A5019818497 @default.
• W4385667060 hasAuthorship W4385667060A5020731258 @default.
• W4385667060 hasAuthorship W4385667060A5028935321 @default.
• W4385667060 hasAuthorship W4385667060A5032750577 @default.
• W4385667060 hasAuthorship W4385667060A5036392227 @default.
• W4385667060 hasAuthorship W4385667060A5041125507 @default.
• W4385667060 hasAuthorship W4385667060A5045676235 @default.
• W4385667060 hasAuthorship W4385667060A5061242940 @default.
• W4385667060 hasAuthorship W4385667060A5070241328 @default.
• W4385667060 hasAuthorship W4385667060A5070987601 @default.
• W4385667060 hasAuthorship W4385667060A5074905580 @default.
• W4385667060 hasAuthorship W4385667060A5088705161 @default.
• W4385667060 hasBestOaLocation W43856670601 @default.
• W4385667060 hasConcept C121332964 @default.
• W4385667060 hasConcept C121608353 @default.
• W4385667060 hasConcept C126322002 @default.
• W4385667060 hasConcept C142424586 @default.
• W4385667060 hasConcept C143998085 @default.
• W4385667060 hasConcept C194409129 @default.
• W4385667060 hasConcept C197934379 @default.
• W4385667060 hasConcept C2776364478 @default.
• W4385667060 hasConcept C2777701055 @default.
• W4385667060 hasConcept C2992053201 @default.
• W4385667060 hasConcept C3875195 @default.
• W4385667060 hasConcept C71924100 @default.
• W4385667060 hasConcept C87355193 @default.
• W4385667060 hasConcept C90924648 @default.
• W4385667060 hasConceptScore W4385667060C121332964 @default.
• W4385667060 hasConceptScore W4385667060C121608353 @default.
• W4385667060 hasConceptScore W4385667060C126322002 @default.
• W4385667060 hasConceptScore W4385667060C142424586 @default.
• W4385667060 hasConceptScore W4385667060C143998085 @default.
• W4385667060 hasConceptScore W4385667060C194409129 @default.
• W4385667060 hasConceptScore W4385667060C197934379 @default.
• W4385667060 hasConceptScore W4385667060C2776364478 @default.
• W4385667060 hasConceptScore W4385667060C2777701055 @default.
• W4385667060 hasConceptScore W4385667060C2992053201 @default.
• W4385667060 hasConceptScore W4385667060C3875195 @default.
• W4385667060 hasConceptScore W4385667060C71924100 @default.
• W4385667060 hasConceptScore W4385667060C87355193 @default.
• W4385667060 hasConceptScore W4385667060C90924648 @default.
• W4385667060 hasIssue "S3" @default.
• W4385667060 hasLocation W43856670601 @default.
• W4385667060 hasLocation W43856670602 @default.
• W4385667060 hasOpenAccess W4385667060 @default.
• W4385667060 hasPrimaryLocation W43856670601 @default.
• W4385667060 hasRelatedWork W2351796763 @default.
• W4385667060 hasRelatedWork W2435227317 @default.
• W4385667060 hasRelatedWork W2518214025 @default.
• W4385667060 hasRelatedWork W2567738959 @default.
• W4385667060 hasRelatedWork W2580450649 @default.
• W4385667060 hasRelatedWork W2737614060 @default.
• W4385667060 hasRelatedWork W2979167002 @default.
• W4385667060 hasRelatedWork W3030208250 @default.
• W4385667060 hasRelatedWork W3084389991 @default.
• W4385667060 hasRelatedWork W4282841510 @default.
• W4385667060 hasVolume "7" @default.
• W4385667060 isParatext "false" @default.
• W4385667060 isRetracted "false" @default.
• W4385667060 workType "article" @default.